



## OPEN ACCESS

APPROVED BY  
Frontiers Editorial Office,  
Frontiers Media SA, Switzerland

\*CORRESPONDENCE  
Frontiers Production Office  
✉ production.office@frontiersin.org

RECEIVED 21 October 2024  
ACCEPTED 25 October 2024  
PUBLISHED 05 November 2024

## CITATION

Frontiers Production Office (2024) Erratum:  
X-linked hypophosphatemic rickets and  
nephrocalcinosis: clinical characteristics of a  
single-center pediatric cohort in North  
America before and after burosumab.  
Front. Pediatr. 12:1514803.  
doi: 10.3389/fped.2024.1514803

## COPYRIGHT

© 2024 Frontiers Production Office. This is an  
open-access article distributed under the  
terms of the [Creative Commons Attribution  
License \(CC BY\)](#). The use, distribution or  
reproduction in other forums is permitted,  
provided the original author(s) and the  
copyright owner(s) are credited and that the  
original publication in this journal is cited, in  
accordance with accepted academic practice.  
No use, distribution or reproduction is  
permitted which does not comply with these  
terms.

# Erratum: X-linked hypophosphatemic rickets and nephrocalcinosis: clinical characteristics of a single-center pediatric cohort in North America before and after burosumab

Frontiers Production Office\*

Frontiers Media SA, Lausanne, Switzerland

## KEYWORDS

XLH, rickets, hypophosphatemia, nephrocalcinosis, burosumab

## An Erratum on

**X-linked hypophosphatemic rickets and nephrocalcinosis: clinical characteristics of a single-center pediatric cohort in North America before and after burosumab**

By Paloian NJ, Boyke-Lohmann LR and Steiner RD (2024). Front. Pediatr. 12: 1430921. doi: 10.3389/fped.2024.1430921

Due to an error, the funder for the article processing charge “Dr. Penniston (Department of Urology, University of Wisconsin-Madison)” was erroneously omitted.

The conflict of interest statement was incorrectly reported as “RS reports consulting fees from Leadiant, Mirum, PTC, and Travers. He is a shareholder of Exact Sciences. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential conflict of interest”.

The correct conflict of interest statement is “RS reports consulting fees from Leadiant, Mirum, PTC, and Travers. He is a shareholder of Exact Sciences. NJ, LB-L, RS, and the funder, Dr. Penniston, are all employed by the University of Wisconsin”.

The publisher apologizes for this mistake. The original version of this article has been updated.